BR100 Increased By (1.77%)
BR30 Increased By (1.96%)
KSE100 Increased By (1.59%)
KSE30 Increased By (1.65%)
BECO 5.62 Increased By ▲ 0.04 (0.72%)
BML 59.51 Decreased By ▼ -1.71 (-2.79%)
BOP 34.61 Increased By ▲ 0.93 (2.76%)
CNERGY 8.08 No Change ▼ 0.00 (0%)
DCL 12.05 Increased By ▲ 0.41 (3.52%)
FCCL 54.40 Increased By ▲ 2.26 (4.33%)
FCSC 5.52 Decreased By ▼ -0.11 (-1.95%)
FFL 18.05 Increased By ▲ 0.04 (0.22%)
FNEL 1.33 Decreased By ▼ -0.02 (-1.48%)
HUMNL 11.07 Increased By ▲ 0.03 (0.27%)
KEL 8.05 Increased By ▲ 0.21 (2.68%)
KOSM 5.88 Increased By ▲ 0.15 (2.62%)
MLCF 90.52 Increased By ▲ 4.01 (4.64%)
NBP 190.17 Increased By ▲ 5.87 (3.19%)
PACE 11.53 Decreased By ▼ -0.12 (-1.03%)
PAEL 41.07 Increased By ▲ 1.11 (2.78%)
PIAHCLA 25.84 Increased By ▲ 0.17 (0.66%)
PIBTL 17.51 Increased By ▲ 0.24 (1.39%)
PPL 225.84 Increased By ▲ 3.17 (1.42%)
PRL 34.63 Increased By ▲ 0.17 (0.49%)
PTC 64.62 Increased By ▲ 0.88 (1.38%)
SEARL 91.38 Increased By ▲ 0.92 (1.02%)
SSGC 26.97 Increased By ▲ 0.30 (1.12%)
TELE 8.93 Increased By ▲ 0.02 (0.22%)
THCCL 69.16 Increased By ▲ 0.69 (1.01%)
TPLP 10.90 Decreased By ▼ -0.30 (-2.68%)
TREET 24.64 Decreased By ▼ -0.06 (-0.24%)
TRG 69.78 Decreased By ▼ -0.81 (-1.15%)
WAVES 11.16 Increased By ▲ 0.05 (0.45%)
WTL 1.27 No Change ▼ 0.00 (0%)
Pakistan Print edition: 2019-12-18

ICI Pakistan strengthens its partnership with AstraZeneca

ICI Pakistan Limited and AstraZeneca UK Limited confirmed the renewal of their longstanding relationship in the cardiovascular and oncology segment. ICI Pakistan is a longstanding distributor of AstraZeneca's high quality life-saving medicines. AstraZenec
Published December 18, 2019 Updated December 17, 2019 11:20pm

ICI Pakistan Limited and AstraZeneca UK Limited confirmed the renewal of their longstanding relationship in the cardiovascular and oncology segment. ICI Pakistan is a longstanding distributor of AstraZeneca's high quality life-saving medicines. AstraZeneca GCC Country President Ismail Shehada visited ICI Pakistan and met with key stakeholders during his two-day visit to renew the existing relationship and explore potential new avenues of partnership to alleviate suffering and build a platform for patients and caregivers to treat high burden of diseases in Pakistan.

Gracing the ceremony at the ICI Pakistan Head Office, Mike Nithavrianakis, British Deputy High Commissioner Karachi and Trade Director for Pakistan, emphasised the importance of building a sustainable ecosystem to provide much needed care to patients in Pakistan.

Speaking on the occasion, ICI Pakistan Chief Executive Asif Jooma said, "ICI Pakistan has been in the pharmaceuticals business since 1993 and seeks to further enhance its global partnerships and introduce innovative products."

Shehada added, "AstraZeneca has an interest in the region and intends to grow its business through providing improved solutions for patients." He further stated, "AstraZeneca is a full healthcare company providing not only innovative molecules but which believes in going beyond medication alone by looking to introduce customised solutions to meet local needs and requirements."-PR

Copyright Business Recorder, 2019

Comments

Comments are closed for this article.